Emmanuelle Quilès Joins Transgene’s Board of Directors
Transgene, a pioneering biotech company specializing in virus-based immunotherapies for cancer treatment, has appointed Emmanuelle Quilès as an independent director to its esteemed Board of Directors. This decision follows the retirement of her predecessor, Philippe Archinard.
Significant Experience in Biotech
Quilès arrives with over 25 years of extensive experience in the pharmaceutical sector, specifically focusing on strategic leadership roles. Most recently, she held a significant position as the Worldwide Vice President for Cardiovascular, Metabolism, and Pulmonary Hypertension at Janssen, which is part of Johnson & Johnson.
Appointment Details
The Board of Directors made a unanimous decision to appoint Quilès, allowing her to serve the remainder of the term previously held by Archinard, which will extend until the next Annual Shareholders' Meeting in 2026. Her official start date is July 9, 2025, representing a new chapter for both her and the company.
Corporate Leadership Insight
Dr. Alessandro Riva, Chairman and CEO of Transgene, expressed his gratitude for Archinard's long-standing contributions to the company. Riva emphasized his confidence in Quilès’s capabilities, believing her wealth of experience and strategic acumen will greatly enhance Transgene's mission to innovate patient care. "Her extensive background will be invaluable as we continue to advance our therapeutics," said Riva.
Quilès' Professional Background
Emmanuelle Quilès is not just an industry leader; she embodies the integration of strategy and innovation in the biotech field. Before her tenure at Janssen, she held numerous high-profile roles at companies including Pfizer, Wyeth, and led her biotech startup, Harmonium. She is also a distinguished graduate of Strasbourg University, where she earned a degree in biotechnology engineering. In recognition of her efforts in advancing health innovation and championing women's leadership, she has been honored as a Knight of the Legion of Honor.
A Diverse and Experienced Board
Transgene’s Board comprises a diverse array of professionals, reflecting a mix of backgrounds and expertise. The current members include Dr. Alessandro Riva, Michel Baguenault de Puchesse, Jean-Luc Bélingard, and several others, ensuring a robust governance structure that promotes strategic oversight.
Board Composition:
The following are the current members of Transgene’s Board of Directors:
- Dr. Alessandro Riva
- Michel Baguenault de Puchesse
- Jean-Luc Bélingard
- Professor Jean-Yves Blay (Independent)
- Sandrine Flory (representing TSGH)
- Benoît Habert
- Marie Landel (Independent)
- Emmanuelle Quilès (Independent)
- Maya Saïd (Independent)
- Carol Stuckley (Independent)
Contact Information
For media inquiries, reach out to:
Caroline Tosch
Corporate and Scientific Communications Manager
+33 (0)3 68 33 27 38
communication@transgene.fr
About Transgene
Transgene is a pioneering biotechnology company focused on the development of innovative cancer immunotherapies. The firm’s clinical-stage portfolio includes viral vector-based immunotherapeutics, with TG4050 being the lead asset. This cancer vaccine exemplifies precision medicine, tailored to fight individual tumors, showcasing the company's commitment to advancing targeted treatments. Transgene's research endeavors also explore novel viral vector-based modalities and oncolytic therapies, exemplifying the company's mission to significantly enhance patient outcomes.
The myvac® platform, a key innovation by Transgene, utilizes patient-specific data to create custom viral-based therapies, highlighting the integration of advanced technology in healthcare. Through partnerships and cutting-edge research, Transgene is poised to lead the way in transforming cancer treatment and improving patient lives.
Frequently Asked Questions
Who is Emmanuelle Quilès?
Emmanuelle Quilès is a seasoned pharmaceutical executive with extensive experience in the industry, recently appointed as an independent director at Transgene.
What is Transgene's primary focus?
Transgene specializes in developing virus-based immunotherapies for cancer treatment, aiming to innovate patient care.
Why did Philippe Archinard retire?
Philippe Archinard announced his retirement, paving the way for new leadership and strategic direction with Emmanuelle Quilès stepping in.
What is the myvac® platform?
The myvac® platform is a proprietary technology that creates personalized viral immunotherapies based on individual patient data, enhancing the precision in cancer treatment.
How can I contact Transgene for investor relations?
For investor inquiries, you can contact Lucie Larguier at +33 (0)3 88 27 91 00 or via email at investorrelations@transgene.fr.
